Air travel in patients suffering from pulmonary hypertension—A prospective, multicentre study

Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.

Pulmonary hypertension (PH) is a complex cardiovascular disorder characterized by elevated mean pulmonary artery pressure >20 mmHg at rest. PH is classified into five groups based on etiology, each with unique underlying causes and pathophysiological mechanisms: pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung disease or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH), and PH with unclear multifactorial mechanisms.

Pulmonary hypertension in sickle cell disease (SCD) is a complex phenomenon resulting from multiple overlapping etiologies, including pulmonary vasoconstriction in the setting of chronic hemolytic...